Abstract Background and Objectives Current cytochrome P450 (CYP) 1A2 and 3A4
ontogeny profiles, which are derived mainly from in vitro studies and incorporated in …

The aim of this review is to discuss our current understanding of the developmental changes
of the drug-metabolizing enzyme cytochrome P450 (CYP) 3A and its impact on drug therapy …

Correct dosing of drugs in neonates, infants and children is hampered by a general lack of
knowledge about drug disposition in this population. Suggested methods to improve our …

The maturation of organ systems during fetal life and childhood exerts a profound effect on
drug disposition. The maturation of drug-metabolising enzymes is probably the predominant …

The accurate prediction of pharmacokinetics (PK) is fundamental to underwriting safety and
efficacy in pediatric clinical trials; age‐dependent PK may be observed with pediatrics …

First‐dose‐in‐children relies on the prediction of clearance from adults for which little
information is available on the accuracy of the scaling‐approaches applied. For CYP3A …

Advances in the basic and clinical sciences of drug actions and safety have been applied
almost exclusively to the largest demographic patient group–adults. Metabolism-dependent …

A paucity of data exists on the disposition and effect of drugs in young children. This
information gap can be reduced by elucidating developmental principles of absorption …

Background and objective Major changes in cytochrome P450 (CYP) 3A activity may be
expected in the first few months of life with, later, relatively limited changes. In this analysis …

Maturation of drug systemic clearance mechanisms during the postnatal period produces
dramatic and rapid changes in an infant's capacity to eliminate drugs. A tentative general …